Previous close | 353.95 |
Open | 354.00 |
Bid | 349.41 x 900 |
Ask | 350.80 x 800 |
Day's range | 348.46 - 354.35 |
52-week range | 282.21 - 387.42 |
Volume | |
Avg. volume | 1,210,545 |
Market cap | 90.228B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 26.31 |
EPS (TTM) | 13.31 |
Earnings date | 05 Feb 2024 - 09 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 400.00 |
With the Nasdaq Composite up by 36% this year, those equities known as the "Magnificent Seven" have done quite a bit of the work. The company in question is biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX).
These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead.
The FDA approved gene-editing therapy Casgevy to treat sickle cell disease. Developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), the one-time treatment harnesses gene editing advancements. Vertex CEO Dr. Reshma Kewalramani says the approach involves extracting a patient's stem cells, correcting the defect in those cells using CRISPR gene editing tools, then re-infusing the edited cells into the patient - relieving painful symptoms. Patients who undergo this $2.2 million procedure may eliminate painful sickle cell crises called VOC's. Kewalramani contrasts the cost against the $4-6 million lifetime price tag for conventional sickle cell management. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.